Compare Novartis AG (NVS) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Stitch Fix Inc — how do they compare? Novartis AG trades at $139.7 (market cap $262.28B), while Stitch Fix Inc trades at $2.9 (market cap $385.60M). The key difference: Novartis AG is far larger — about 680.2× Stitch Fix Inc's market cap, and Novartis AG pays a 3.45% dividend while Stitch Fix Inc pays none. Which is the better fit depends on your goals.
| NVS | SFIX | |
|---|---|---|
Market Cap | $262.28B | $385.60M |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $5.80 |
52-Week Low | $121.80 | $2.89 |
Enterprise Value | $303.60B | $273.32M |
Dividend Yield | 3.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, reflecting ongoing investor caution despite recent operational improvements. The stock is technically bearish with key moving averages signaling selling pressure, while fundamentals show a narrowing net loss margin to -2.27% in 2025 from -9.64% in 2024, alongside a low price-to-sales ratio of 0.3. Recent news highlights AI-driven personalization efforts and exclusive brand collaborations aimed at boosting client engagement and revenue per user.
The outlook remains mixed; cost controls and revenue stabilization offer a path to profitability, but persistent net losses and competitive pressures pose risks. Analyst sentiment is cautious with a 63.64% hold rating, suggesting investors await clearer signs of a sustained turnaround before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
